External reports (aggregated public sources), Value Investors Club

Value Investors Club

Value Investors Club (.com) is an exclusive online investment club where top investors share their best ideas. Content available at the above link/PDF preview is an external article authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>Abeona is developing a cell therapy for the rare disease RDEB, with FDA review ongoing and a target action date of May 25th</li><li>The therapy is expected to have a significant impact on RDEB patients, who face severe skin and GI issues due to a lack of specific collagen</li><li>With a niche business model focused on treating a small patient population, Abeona anticipates generating over $100 million in free cash flow and potentially offering significant upside for investors.</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

Abeona is developing a cell therapy for the rare disease RDEB, with FDA review ongoing and a target action date of May 25thThe therapy is expected to have a significant impact on RDEB patients, who face severe skin and GI issues due to a lack of specific collagenWith a niche business model focused on treating a small patient population, Abeona anticipates generating over $100 million in free cash flow and potentially offering significant upside for investors.This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Abeona Therapeutics Inc (ABEO) - Thursday, Feb 15, 2024